Stanford Researchers Use Urinary Cell-Free RNA to Detect Bladder Cancer Recurrence

Stanford University Researchers Detect Bladder Cancer Through Urine RNA Sequencing

Scientists at Stanford University have discovered that cell-free RNA circulating in urine can identify bladder cancer and track whether residual cancer cells remain after treatment, according to TechNews 科技新報. The method provides an alternative to invasive cystoscopy procedures commonly used to monitor patients for recurrence.

Key Clinical Takeaways:

• Stanford University researchers developed a urine cell-free RNA sequencing technique that captures short RNA fragments to detect molecular clues of bladder cancer without direct tumor tissue extraction.
• The urine RNA diagnostic model demonstrated a 95% sensitivity rate in validation tests, correctly flagging 95 out of 100 localized bladder cancer cases while maintaining a 10% false-positive rate.
• Analysis of 36 treated patients showed that post-treatment RNA signals disappeared in patients without recurrence, whereas patients who experienced high-grade recurrence retained detectable cancer-related RNA.

Isolating Short RNA Fragments From Urine Samples

Cell-free RNA floats freely outside intact cells within body fluids. While cancer cells release these RNA strands, urine typically contains scarce and highly fragmented RNA, rendering comprehensive analysis difficult. The Stanford research team overcame this limitation by first capturing short RNA fragments from urine samples and then applying genetic sequencing to evaluate thousands of gene signals. Healthy test subjects predominantly showed cell-free RNA originating from urogenital tissues such as the bladder, kidneys, and prostate. By contrast, samples from bladder cancer patients exhibited gene expression signatures closely mirroring actual tumor tissue.

Urine RNA Detects Residual Bladder Cancer and Recurrence

Following initial interventions, patients with bladder cancer face a persistent risk of recurrence, necessitating ongoing monitoring. The study tracked 36 individuals undergoing treatment to determine if urine RNA could detect residual disease. Prior to surgery, all participants showed detectable bladder cancer RNA in their urine. For patients who remained cancer-free, these molecular signals faded over time. Conversely, patients who developed high-grade recurrences continued to display cancer-related RNA following treatment.

Building on these tracking capabilities, the investigators constructed a predictive model using data from 114 patients to forecast therapeutic responses. The model separated patients likely to respond well from those with poor outcomes, aligning closely with subsequent recurrence risks. Investigators published these findings in Nature Medicine, pointing toward future clinical applications where non-invasive liquid biopsies might supplement traditional tumor grading and sizing metrics when physicians evaluate treatment strategies.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on Stanford: Stanford researchers find protein target to regenerate knee cartilage